SG Americas Securities LLC Increases Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

SG Americas Securities LLC lifted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 77.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,329 shares of the company's stock after buying an additional 6,253 shares during the quarter. SG Americas Securities LLC's holdings in Disc Medicine were worth $711,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC lifted its holdings in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Disc Medicine in the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its stake in shares of Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Disc Medicine during the fourth quarter worth about $235,000. Finally, Fiduciary Trust Co acquired a new position in Disc Medicine during the fourth quarter worth about $257,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Trading Up 6.4%

Shares of NASDAQ:IRON traded up $3.32 during trading on Tuesday, reaching $55.00. The stock had a trading volume of 561,372 shares, compared to its average volume of 342,520. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.90 billion, a P/E ratio of -14.03 and a beta of 0.73. The business has a fifty day moving average price of $47.45 and a 200-day moving average price of $52.64. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IRON shares. Scotiabank lifted their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Raymond James Financial initiated coverage on Disc Medicine in a report on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 price objective for the company. Cantor Fitzgerald boosted their target price on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. BMO Capital Markets raised their price target on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, June 17th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Disc Medicine presently has a consensus rating of "Buy" and a consensus price target of $96.70.

Insider Activity at Disc Medicine

In other Disc Medicine news, CFO Jean M. Franchi sold 2,000 shares of Disc Medicine stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $52.26, for a total value of $104,520.00. Following the completion of the sale, the chief financial officer now owns 67,530 shares in the company, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Jacob Savage sold 2,996 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $50.00, for a total transaction of $149,800.00. Following the completion of the sale, the insider now directly owns 56,725 shares in the company, valued at $2,836,250. This represents a 5.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,773 shares of company stock worth $693,794. 4.24% of the stock is currently owned by insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.